636-P: Diabetes Providers Value CGM Data Despite Challenges in Data Review Process

Abstract

People with diabetes (PWD) benefit from continuous glucose monitoring (CGM), yet CGM uptake in the US remains low. While diabetes care providers are key facilitators of CGM provision, data on provider behavior related to CGM use and CGM generated data is limited. In March 2020, we conducted a national survey of providers caring for PWD on CGM-related opinions, facilitators and barriers to CGM prescription, data review practices, and reimbursement. Descriptive statistics were used to report prevalence of Likert scale answers to a 55-question survey. Of 182 survey respondents caring for PWD using CGM, 75% were at academic medical centers, 66% were endocrinologists, and 70% practiced in urban settings. Nearly 70% of providers reported CGM use in a majority of their patients with type 1 diabetes. CGM use in patients with type 2 diabetes was low, with half the providers reporting <10% CGM use. All respondents believed CGM improved quality of life and could help optimize diabetes control. Nearly all providers reviewed CGM data each visit (94%) and directly involved patients in data review (90%). Only 14% of providers reviewed CGM data outside of a scheduled visit without prompting from patients or their family members. Most providers (81%) reported their CGM data review was valued by patients although only half (55%) reported having adequate time or an efficient process to do so. Most providers included CGM data in the electronic health record but only 41% had an efficient process for data capture. The majority of providers (79%) sought reimbursement for CGM interpretation during a visit, but a minority (41%) sought reimbursement for interpretation outside of visits. Despite uniform support for CGM by providers, inadequate time and inefficient data review processes are ongoing challenges. Improvements in data access and integration, supportive clinical infrastructure, and decreased administrative burden to obtain CGM, are facilitators of effective use of CGM-data by providers and necessitate ongoing attention. Disclosure T. Kompala: Consultant; Self; Eli Lilly and Company, Employee; Self; Livongo. J. C. Wong: Advisory Panel; Self; Provention Bio, Inc., Research Support; Self; Dexcom, Inc., Tandem Diabetes Care. A. B. Neinstein: Consultant; Self; Eli Lilly and Company, Intuity Medical , Medtronic, Roche Diabetes Care, Steady Health.